Johnson & Johnson

JNJNYSEHealthcare● Active

$232.77

+$4.60(+2.02%)

Market Cap$560.3B

P/E Ratio—

52W High$251.71

52W Low$149.04

Avg Volume7.7M

Open$230.00

Beta0.26

PE Ratio Market Cap Forecast

Johnson & Johnson (JNJ) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

jnj · pe ratio · data through Dec 28, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Johnson & Johnson (JNJ) measures how much investors pay for each dollar of the company's trailing earnings. JNJ's current PE ratio of 27.05x is calculated by dividing its stock price of $232.77 by its TTM earnings per share of $8.60. +32.7% elevated vs 5Y avg 20.4x

27.05x

P/E Ratio (TTM)+32.7%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-28

Forward P/E

18.23x

FY2027 est. EPS $12.77

Based on 13 analysts

EPS (TTM)

$8.60

TTM · diluted EPS

PEG Ratio

-6.13

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Johnson & Johnson SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual

PE Ratio (TTM)

5Y Avg 20.4x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 20 fiscal years · Front-end computed

Average

32.6x

20-yr mean

Median

18.6x

20-yr midpoint

Minimum

11.3x

Lowest year

Maximum

288.3x

Highest year

27.1x ← Now

11.3x
MinQ1 · 25%18.6x
MedianQ3 · 75%288.3x
Max

Historically Elevated

At 27.05x, JNJ's current P/E is higher than in 90% of its annual fiscal year readings over the past 20 years — historically elevated.

90th percentileHigher than 18 of 20 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Drug Manufacturers - General · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
Johnson & JohnsonYou JNJ	$560.3B	27.05x	-15.5%	$8.60
AbbVie Inc. ABBV	$401.5B	96.26x	+200.8%	$2.37
Amgen Inc. AMGN	$188.7B	22.84x	-28.7%	$14.33
AstraZeneca PLC AZN	$288.4B	26.53x	-17.1%	$6.62
Gilead Sciences, Inc. GILD	$160.4B	17.94x	-43.9%	$6.84
Merck & Co., Inc. MRK	$298.3B	14.43x	-54.9%	$7.30
Novo Nordisk A/S NVO	$190.9B	14.05x	-56.1%	$23.03
Industry Average 6 peers with valid PE	—	32.01x	baseline	—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2025-12-28Latest FY2025	18.81x	$11.04	-23.3%
2024-12-29 FY2024	24.53x	$5.84	+117.2%
2023-12-31 FY2023	11.30x	$13.88	-56.1%
2023-01-01 FY2023	25.73x	$6.86	+19.1%
2022-01-02 FY2022	21.60x	$7.94	-22.9%
2021-01-03 FY2021	28.00x	$5.59	+10.2%
2019-12-31 FY2019	25.40x	$5.74	+13.1%
2018-12-31 FY2018	22.46x	$5.75	-92.2%
2017-12-31 FY2017	288.31x	$0.48	+1429.3%
2016-12-31 FY2016	18.85x	$6.11	+2.6%

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $232.77 ÷ $8.60 = 27.05x

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

JNJ pe ratio · 6 questions

JNJ's current PE ratio is 27.05x as of 2026-06-08, based on a stock price of $232.77 and TTM EPS of $8.60. Data sourced from Financial Modeling Prep via JNJ's SEC 10-K and 10-Q filings.

JNJ PE ratioWhat is JNJ PE ratioCurrent PE ratio of JNJJNJ PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Johnson & Johnson SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08